engineered a vesicular stomatitis virus (VSV) to express an scFv-anti-PD-L1, demonstrating that this system shows a potent therapeutic effect in a lung carcinoma mouse model (35), while Tanoue et al., in 2017, demonstrated that the PD-L1 mini body expressed by a system of Onc.Ads and helper-dependent Ads (HD-Ad) blocks, with high efficacy, the PD-1/PD-L1 pathway enhanced the antitumoral effect in a prostate cancer engraft mouse model. This evidence concerns the gene CD274 and prostate carcinoma.